We are live on ! Find out more

1,033 hedge funds and large institutions have $21.7B invested in Labcorp in 2022 Q1 according to their latest regulatory filings, with 85 funds opening new positions, 368 increasing their positions, 397 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $186M | Put options by funds: $59.2M

0.12% more ownership

Funds ownership: 102.41%102.54% (+0.12%)

7% less repeat investments, than reductions

Existing positions increased: 368 | Existing positions reduced: 397

3% less funds holding

Funds holding: 1,0601,033 (-27)

17% less first-time investments, than exits

New positions opened: 85 | Existing positions closed: 102

18% less capital invested

Capital invested by funds: $26.4B → $21.7B (-$4.72B)

33% less funds holding in top 10

Funds holding in top 10: 3020 (-10)

Holders
1,033
Holders Change
-27
Holders Change %
-2.55%
% of All Funds
16.24%
Holding in Top 10
20
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-33.33%
% of All Funds
0.31%
New
85
Increased
368
Reduced
397
Closed
102
Calls
$186M
Puts
$59.2M
Net Calls
+$127M
Net Calls Change
+$45.1M

LH Hedge Fund Activity: Q1 2022 in Review

1,033 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Labcorp (LH) for Q1 2022, worth a combined $21.7B — down 18% from $26.4B a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of LH and 85 opened new positions — a net loss of 17 holders — while 397 trimmed existing stakes and 368 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $472M. The largest seller was Melvin Capital Management, cutting an estimated $329M.

  • 1,033 institutional investors held Labcorp (LH) as of Q1 2022, down from 1,060 in Q4 2021.
  • Funds reported $21.7B of Labcorp stock for Q1 2022, down 18% quarter-over-quarter.
  • 85 funds opened new Labcorp positions in Q1 2022 and 102 closed out, a net change of -17 holders.
  • The largest Labcorp buyer in Q1 2022 was T. Rowe Price Associates, an estimated $472M added.
  • The largest Labcorp seller in Q1 2022 was Melvin Capital Management, an estimated $329M sold.

Based on aggregated 13F filings for Q1 2022.